Cingulate Investor Relations Material
Latest events
Q2 2025
19 Aug, 2025
Q1 2025
8 May, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Cingulate Inc
Access all reports
Cingulate Inc. is a biopharmaceutical company focused on developing treatments for central nervous system disorders. The company specializes in precision drug delivery technology to enhance the efficacy and control of medications. Its primary research targets attention-deficit/hyperactivity disorder (ADHD) and other cognitive and psychiatric conditions. Cingulate leverages its proprietary Precision Timed Release (PTR) platform to develop extended-release formulations for improved patient outcomes. The company is headquartered in Kansas City, Kansas, and its shares are listed on the NASDAQ.
Latest articles
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
)
Maziar Mike Doustdar: Novo Nordisk's New CEO
A portrait of the pharmaceutical giant's new CEO, who assumes the position at a critical time for the company in its competition with Eli Lilly.
12 Aug 2025
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
Ticker symbol
CING
Country
🇺🇸 United States